U.S. vaccine advisers unanimously favor Pfizer/BioNTech shot after approval

  • 📰 Reuters
  • ⏱ Reading Time:
  • 33 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 17%
  • Publisher: 97%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) on Monday unanimously recommended the Pfizer Inc and BioNTech SE COVID-19 vaccine for people age 16 and older, an important step that could help accelerate vaccine mandates in the United States.

Vials of the Pfizer-BioNTech vaccine are pictured in a vaccination centre in Geneva, Switzerland, February 3, 2021. REUTERS/Denis Balibouse

The Food and Drug Administration last week granted full approval to the vaccine that was previously available under the agency's emergency use authorization , which had allowed the shots to be rolled out rapidly to Americans. Some panel members said increasing vaccinations before the fall season was critical to getting children back to schools safely.

CDC staff presented available data on the need for boosters and said, at this point it may be difficult to determine whether immunity from prior vaccination is waning over time or if the vaccines are just less able to prevent infection by the highly-transmissible Delta variant.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in HEALTH

Health Health Latest News, Health Health Headlines